Hansen LBS, Roager HM, Sndertoft NB, Gbel RJ, Kristensen M, Valls-Colomer M, et al
Customer Reviews (9) WOW WOW this is seriously good stuff
The post says yes
According to FDA labeling and American Diabetes Association guidance, the risk of hypoglycemia is significantly higher when tirzepatide is used with insulin or sulfonylureas compared to tirzepatide monotherapy
[15] [37] [38] In August 2025, the Food and Drug Administration (FDA) expanded the indication for semaglutide (as Wegovy) to include the treatment of noncirrhotic metabolic-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH), with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis) in adults
You can find a wealth of information by exploring channels dedicated to peptide science, such as the MorelliFit channel, which provides great insights into the practical application and science of these compounds